The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients

References

• Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407–17.
   PubMed Web of Science ®Google Scholar
• Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006;45:885–9.
   PubMed Web of Science ®Google Scholar
• Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in patients with rheumatoid arthritis. J Clin Nurs 2007;16:377–83.
   PubMed Web of Science ®Google Scholar
• van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010;49:1294–302.
   PubMed Web of Science ®Google Scholar
• Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993;20:790–6.
   PubMed Web of Science ®Google Scholar
• Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 1998;41:2230–7.
   PubMed Web of Science ®Google Scholar
• Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JMGW, Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 1998;37:1042–6.
   PubMedGoogle Scholar
• Wolfe F, Michaud K, Pincus T. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 2004;31:2115–20.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, . Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007;25:838–46.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006;55:287–93.
   PubMed Web of Science ®Google Scholar
• Netea MG, Kullberg BJ, Vonk AG, Verschueren I, Joosten LAB, van der Meer JWM. Increased voluntary exercise in mice deficient for tumour necrosis factor-alpha and lymphotoxin-alpha. Eur J Clin Invest 2007;37:737–41.
   PubMed Web of Science ®Google Scholar
• Hoving JL, Bartelds GM, Sluiter JK, Sadiraj K, Groot I, Lems WF, . Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009;38:246–50.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, . The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
   PubMed Web of Science ®Google Scholar
• Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford). Published online: 22 April 2011. doi:10.1093/rheumatology/ker162.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo MLL, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease-activity scores that include 28-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van ‘t HM, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579–81.
   PubMed Web of Science ®Google Scholar
• Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, van der Meer JWM, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383–92.
   PubMed Web of Science ®Google Scholar
• Vercoulen JHMM, Alberts M, Bleijenberg G. The Checklist Individual Strength. Gedragstherapie 1999;32:131–6.
   Google Scholar
• van Hoogmoed D, Fransen J, Bleijenberg G, van Riel PLCM. How to assess fatigue in rheumatoid arthritis: validity and reliability of the Checklist Individual Strength. Arthritis Rheum 2008;58:S868.
   Google Scholar
• Boers M, Jacobs JWG, Vlieland TPMV, van Riel PLCM. Consensus Dutch health assessment questionnaire. Ann Rheum Dis 2007;66:132–3.
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
   PubMed Web of Science ®Google Scholar
• Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997;35:785–91.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, . Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563–71.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004;363:1728–31.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, . Randomized double-blind comparison of chimeric monoclonal-antibody to tumor-necrosis-factor-alpha (Ca2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.
   PubMed Web of Science ®Google Scholar